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Abstract
Aims SGLT2 inhibitors are a new class of oral hypogly-
cemic agents used in type 2 diabetes (T2DM). Their
effectiveness in maturity onset diabetes of the young
(MODY) is unknown. We aimed to assess the response to a
single dose of 10 mg dapagliflozin in patients with Hepa-
tocyte Nuclear Factor 1 Alpha (HNF1A)-MODY, Gluco-
kinase (GCK)-MODY, and type 2 diabetes.
Methods We examined 14 HNF1A-MODY, 19 GCK-
MODY, and 12 type 2 diabetes patients. All studied indi-
viduals received a single morning dose of 10 mg of dapa-
gliflozin added to their current therapy of diabetes. To
assess the response to dapagliflozin we analyzed change in
urinary glucose to creatinine ratio and serum 1,5-Anhy-
droglucitol (1,5-AG) level.
Results There were only four patients with positive urine
glucose before dapagliflozin administration (one with
HNF1A-MODY, two with GCK-MODY, and one with
T2DM), whereas after SGLT-2 inhibitor use, glycosuria
occurred in all studied participants. Considerable changes in
mean glucose to creatinine ratio after dapagliflozin admin-
istration were observed in all three groups (20.51 ± 12.08,
23.19± 8.10, and 9.84± 6.68 mmol/mmol for HNF1A-
MODY, GCK-MODY, and T2DM, respectively, p< 0.001
for all comparisons). Post-hoc analysis revealed significant
differences in mean glucose to creatinine ratio change
between type 2 diabetes and each monogenic diabetes in
response to dapagliflozin (p= 0.02, p= 0.003 for HNF1-A
and GCK MODY, respectively), but not between the two
MODY forms (p= 0.7231). Significant change in serum
1,5-AG was noticed only in T2DM and it was −6.57±
7.34 mg/ml (p= 0.04).
Conclusions A single dose of dapagliflozin, an SGLT-2
inhibitor, induces higher glycosuria in GCK- and HNF1A-
MODY than in T2DM. Whether flozins are a valid ther-
apeutic option in these forms of MODY requires long-term
clinical studies.
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Introduction
Maturity Onset Diabetes of the Young (MODY) is esti-
mated to account for 1–2% of all cases of diabetes, which
may correspond to hundreds of thousands of patients in
Europe. The most typical clinical features of MODY
include early age of diagnosis (usually in the 2nd and 3rd
decade of life), positive family history, autosomal dominant
mode of inheritance, absence of autoantibodies typical for
type 1 diabetes mellitus (T1DM), and lack of obesity [1].
Most MODY cases result from mutations within the hepa-
tocyte nuclear factor 1 alpha (HNF1A) and glucokinase
(GCK) genes [2, 3].
Mutations in the HNF1A gene, which encodes a tran-
scription factor that regulates the expression of many other
genes, lead to insulin secretion impairment [4]. As a result,
patients with HNF1A-MODY require pharmacotherapy and
often develop chronic complications [5, 6]. These patients
typically respond well to treatment with sulfonylurea, which
increases insulin release from beta cells and is currently
considered the treatment of choice for patients with
HNF1A-MODY [7, 8]. As the nature of the beta-cell defect
in HNF1A-MODY is progressive, this treatment frequently
requires further intensification with additional hypogly-
cemic agents. The extra-pancreatic features of HNF1A-
MODY include glycosuria due to a low renal threshold for
glucose [9], which has been linked to decreased sodium/
glucose co-transporter 2 (SGLT2) expression in tubular
cells [10].
Meanwhile, in GCK-MODY glucose homeostasis is less
affected than in HNF1A-MODY. GCK-MODY subjects are
characterized by mild fasting hyperglycemia. It is generally
accepted that most diabetic GCK mutation carriers do not
need hypoglycemic treatment [11]. They usually do not
develop advanced chronic microvascular complications of
diabetes, although, the prevalence of background retino-
pathy is rather high, reaching 30% according to British data
[12]. Moreover, there is also some evidence on abnormal-
ities in surrogate cardiovascular outcomes in GCK mutation
carriers [13]. Therefore, clinicians would probably consider
initiation of treatment in some GCK-MODY patients.
Regrettably, pharmacological treatment including either
insulin, or oral hypoglycemic agents, such as metformin or
SU, turned out to be ineffective in this form of MODY,
probably due to the fact that the switch-on of the counter-
regulatory response occurs at higher glucose level than in
healthy subjects [14, 15]. So, there is still a need to test new
available treatments in both of the two most frequent sub-
types of MODY [1]. This is particularly important because
thanks to the widening use of next-generation sequencing a
growing number of patients with a genetic diagnosis of
MODY will be identified [16, 17].
Recently a new group of oral hypoglycemic agents—
SGLT2 inhibitors—were introduced into the market and
made available for patients with diabetes. These inhibitors
block the low-affinity, high capacity glucose transporter
located in the proximal tubule in the kidneys that is
responsible for 90% of glucose reabsorption. Therefore,
SGLT2 inhibitors can reduce plasma glucose levels by
producing glycosuria [18]. A single dose of the SGLT2
inhibitor dapagliflozin was shown to be enough to produce
glycosuria and the effect lasted up to 24 h [19, 20]. As
mentioned above, the expression of SGLT2 and the function
of the SGLT2 protein are reduced among HNF1A-MODY
individuals [10]. Therefore, it can hypothesized that
response to SGLT2 inhibitors, such as dapagliflozin, may be
compromised among HNF1A-MODY individuals, thus
influencing their efficacy in these patients.
Aim of the study
We aimed to assess the response to a single dose of 10 mg
dapagliflozin in patients with HNF1A-MODY and to
compare it with T2DM and GCK-MODY individuals by
measuring changes in urinary glucose to creatinine ratio
(GCR) and in serum 1,5-anhydroglucitol (1,5-AG) level,
which indirectly reflects episodes of glycosuria. 1,5-AG is a
short-term marker of glycemic control (mainly postprandial)
that corresponds to the preceding 1–2 weeks. In a state of
glycosuria, renal reabsorption of 1,5-AG is decreased, as
this particle competes with glucose for reabsorption in the
proximal renal tubule, which results in its lower serum level
[21–24]. Additionally. we assess GCR change as a diag-
nostic tool to distinguish between T2DM and MODY.
Materials and methods
Study population
The studied group included 14 HNF1A-MODY patients, 19
GCK-MODY individuals, and 12 T2DM subjects. All
MODY patients had a heterozygous loss-of-function
mutation either in the HNF1A or GCK gene identified by
direct DNA sequencing. HNF1A-MODY patients were
members of 13 families, whereas GCK-MODY individuals
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were members of 17 families. T2DM individuals were
ascertained as described earlier [25].
We included patients with at least 2 years duration of
diabetes and without diabetic kidney disease defined as
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) estimated glomerular filtration rate (eGFR) <60
ml/min/1.73 m2 diagnosed prior to inclusion in the study.
We excluded patients with a hemoglobin A1c (HbA1c)
>9.0% (75 mmol/mol), those who were on insulin or steroid
therapy, or taking drugs affecting renal function (e.g., loop
diuretics). Pregnancy was also an exclusion criterion. We
gathered clinical data on the study individuals from their
medical records. Additionally, we collected the information
from the standard questionnaire and performed a basic
physical examination. All studied individuals received a
single morning dose of 10 mg of dapagliflozin. The patients’
current therapy, including use of other hypoglycemic
agents, was not changed. To assess the glycosuric response
to dapagliflozin the following analyses were performed in
all subjects: (1) three measurements of urinary glucose and
creatinine concentrations: one in the morning on the dapa-
gliflozin administration day (Day 0), one 8–12 h after
administration of the drug, and one in the morning on Day
+1; (2) two measurements of serum 1,5-AG level: one in
the morning on Day 0 and one in the morning on Day +1.
Additionally, we performed two measurements of fasting
plasma glucose (FPG): one in the morning on Day 0, and
one in the morning on Day +1, as well as two daily glucose
profiles performed with glucose meters by participants
(fasting, before and 2 h after main meals): one on the day
before drug administration (Day −1) and one on the
dapagliflozin administration day. Urine glucose concentra-
tion below 1.0 mmol/l was considered negative. Urinary
GCR was calculated for all three urine measurements. 1,5-
AG was measured in fasting conditions using a competitive
inhibition enzyme immunoassay (ELISA; Cloud Clone
Corp., Houston, TX 77,082, USA). The assay has a sensi-
tivity of 0.7 µg/ml, the intra- and inter-assay coefficients of
variation of the ELISA were <10%. The absorbance was
finally measured in a microplate reader (BioTek Instru-
ments, Winooski, VT, USA). The study was approved by
the local Bioethics Committee. All participants gave written
informed consent.
Statistical analysis
Statistical analysis was performed using Statistica Software
v. 12.0 (StatSoft, Tulsa, OK, USA) and MedCalc Statistical
Software v 16.8.4 (MedCalc Software bvba, Ostund, Bel-
gium). All performed tests were two-tailed and a p-value
<0.05 was considered significant. The Kolmogorov-
–Smirnov test was used to determine the normal distribution
of variables. p-values were calculated with the t-test and the
one-way ANOVA or nonparametric Kruskall–Wallis test,
followed by post hoc-tests. Multivariate linear regression
analysis (backward selection) was used to assess differences
in mean GCR and 1,5-AG change between studied groups
after adjustment for gender, age, diabetes duration, body
mass index (BMI), eGFR, FPG, and HbA1c. Diagnostic
performance (i.e., the ability of GCR after dapagliflozin
administration to identify MODY and T2DM) was assessed
using the receiver operating characteristics (ROC) curve.
The standard error (SE) of the area under the ROC curve
(AUC) and 95% confidence intervals (95% CI) were cal-
culated using DeLong’s method [26].
Results
The characteristics of the study participants are presented in
Table 1. There were differences between the study groups
for age, BMI and HbA1c. The patients with T2DM were
older, more obese, and were characterized by worse gly-
cemic control than HNF1A-MODY and GCK-MODY
subjects what is in line with the way how groups were
defined. In post-hoc analyses, we found no differences
between HNF1A-MODY and GCK-MODY subjects
according to age, BMI and HbA1c. There were no differ-
ences between study groups in terms of sex distribution and
kidney function. During the study examination we diag-
nosed one patient with chronic kidney disease (eGFR 47 ml/
min/1.73 m2) and his results were included in the analyses.
Results presented by that patient were not detected as out-
liers. All study participants were free from proliferative
diabetic retinopathy. Almost all GCK gene mutation carriers
were on dietary therapy only; only one GCK-MODY
patient (a 67-year old female) was on metformin. Among
the 14 HNF1A-MODY individuals, 12 were on SU, one
patient (a 30-year female with polycystic ovary syndrome)
was on metformin, and one was on dietary therapy only.
Slightly more than half of patients with T2DM were on
combined therapy with metformin and SU or DPP4 inhi-
bitors; other T2DM patients were on metformin
monotherapy.
There were only four patients with positive urine glucose
before dapagliflozin administration—one patient with
HNF1A-MODY, two subjects with GCK-MODY, and one
individual with T2DM. After 8–12 h of dapagliflozin
administration glycosuria occurred in all studied patients
and the effect persisted for 24 h in every participant. Sig-
nificant differences in urinary GCR after 24 h of dapagli-
flozin administration were observed in the studied groups as
this rose by 20.51± 12.08, 23.19± 8.10, and 9.84± 6.68
mmol/mmol for HNF1A-MODY (p= 0.0000), GCK-
MODY (p= 0.0000), and T2DM (p= 0.0003), respec-
tively. These mean changes in urinary GCR were different
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between the groups (p= 0.001). Post-hoc analysis revealed
significant differences in mean GCR rise between the
T2DM and MODY forms of diabetes (p= 0.02 and p=
0.003 for HNF1-MODY and GCK-MODY, respectively);
however, no difference between the HNF1A-MODY and
GCK-MODY groups were observed (p= 0.72). Never-
theless, in multivariate linear regression (R2= 27%), the
only significant variable remained BMI (p= 0.0001), but
not type of diabetes. Similar results in GCR change in the
evening on Day 0 (after 8–12 h of dapagliflozin adminis-
tration) were observed.
As expected, mean 1,5-AG level on Day 0 was the
lowest in HNF1A-MODY. The significant change in mean
serum 1,5-AG was noticed only in T2DM, for which it was
−6.57± 7.34 mg/ml (p= 0.04), but not in HNF1A-MODY
(−0.10± 4.21 mg/ml, p= 0.94) or GCK-MODY (−0.86±
4.16 mg/ml, p= 0.38). In the one-way ANOVA, a con-
siderable difference in mean 1,5-AG change among the
studied groups was found (p= 0.02). Post-hoc analyses
revealed significant discrepancy in 1,5-AG change between
T2DM and HNF1A-MODY (p= 0.04) and a borderline
difference between T2DM and GCK-MODY (p= 0.07). In
the multivariate linear regression (R2= 27%), the only
significant variable was initial serum 1,5-AG level (p=
0.0009).
Mean initial FPG was significantly lower in the HNF1-
MODY group than in the GCK-MODY and T2DM groups.
There were no significant differences in FPG between the
GCK-MODY and T2DM groups. Subgroup analyses
revealed significant mean FPG reduction in GCK-
MODY (0.50 ± 0.72 mmol/l, p= 0.007), but not in
HNF1A-MODY (0.14 ± 0.90 mmol/l, p= 0.56) and T2DM
(0.23 ± 1.20 mmol/l, p= 0.52). ANOVA analysis revealed
no differences in the degree of FPG reduction at this sample
size.
Mean initial average daily glucose level based on self-
monitoring of blood glucose (SMBG) was the lowest in the
HNF1A-MODY (p= 0.01). No significant reduction in
mean average daily glucose was found in the studied groups
(−0.21± 0.61 mmol/l, p= 0.2154; −0.09± 0.51 mmol/l, p
= 0.4686; −0.27± 1.27 mmol/l, p= 0.4710 for HNF1A-
MODY, GCK-MODY and T2DM, respectively).
Table 1 Clinical characteristic and biochemical measurements of the study group
Characteristic HNF1A-MODY GCK-MODY T2DM p-value
N 14 19 12 NA
Male/female (n) 7/7 7/12 8/4 0.17a
Age at examination (years) 34.1± 11.0 40.3± 10.8 61.8± 5.6 0.0000b
Time from diabetes diagnosis (years) 11.4± 6.8 8.7± 7.1 5.8± 4.2 0.10b
BMI (kg/m2) 24.4± 4.9 23.4± 2.8 31.3± 5.3 0.0000b
eGFR CKD-EPI (ml/min/1.73 m2) 98.1± 15.1 99.9± 15.6 87.7± 15.9 0.10b
HbA1c (%, mmol/mol) 6.0± 0.7, 42.0± 5.3 6.4± 0.4, 46.0± 2.0 6.9± 0.9, 52.0± 7.5 0.03c
hsCRP (mg/l) 0.52± 0.30 1.12± 1.57 1.60± 1.15 0.09b
GCR (Day 0)—patients with positive urinary glucose
only (mmol/mmol, n)
0.15, 1 0.17± 0.18, 2 2.01, 1 NA
GCR change (8–12 h after dapagliflozin administration)
(mmol/mmol)
35.64± 14.10 38.72± 9.65 19.37± 18.76 0.001b
GCR change (Day +1—Day 0) (mmol/mmol) 20.51± 12.08 23.19± 8.10 9.84± 6.68 0.001b
1,5-AG (Day 0) (mg/ml) 8.75± 8.43 19.61± 9.22 26.72± 9.03 0.0000b
1,5-AG change (Day +1 −Day 0) (mg/ml) −0.09± 4.21 −0.86± 4.16 −6.57± 7.34 0.02b
FPG (Day 0) (mmol/l) 5.60± 1.02 6.82± 0.71 7.73± 2.25 0.005c
FPG change (Day +1—Day 0) (mmol/l) −0.14± 0.90 −0.50± 0.72 −0.23± 1.20 0.51b
Average daily glucose in SMBG (Day −1) (mmol/l) 6.02± 1.03 6.99± 0.50 7.60± 1.77 0.008c
Average daily glucose in SMBG (Day 0) (mmol/l) 5.81± 0.87 6.90± 0.59 7.32± 1.58 0.002c
Average daily glucose change in SMBG (Day 0—Day
−1) (mmol/l)
−0.21± 0.61 −0.09± 0.51 −0.27± 1.27 0.84c
Data are presented as mean± standard deviation
1,5-AG 1,5-Anhydroglucitol, FPG fasting plasma glucose, GCR glucose to creatinine ratio, hsCRP high sensitive C-reactive protein, NA not
applicable, n number of cases, SMBG self-monitoring of blood glucose
a χ2 test
b One-way analysis of variance (ANOVA)
c Kruskal–Wallis test
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Additionally, we assessed change in GCR (after 24 h of
dapagliflozin administration) as a biomarker in differential
diagnosis for subtypes of diabetes. The ROC curves
showing the ability of GCR change to differentiate between
the three subtypes of diabetes are presented in Fig. 1. The
ROC curve analysis performed for T2DM and HNF1A-
MODY revealed an AUC of 0.80 (95% CI 0.60–0.93) with
sensitivity 78.6% (95% CI 49.2–95.3) and specificity 75.0%
(95% CI 42.8–94.5). The results for T2DM and GCK-
MODY were: 0.90 (0.74–0.98), 94.7% (74.0–99.9) and
75.0% (42.8–94.5), respectively. For GCK-MODY and
HNF1A-MODY, AUC was 0.63 (95% CI 0.45–0.79), with
a sensitivity of 84.2% (95% CI 60.4–96.6%) and specificity
of 57.1% (95% CI 28.9–82.3%).
Discussion
In this small-scale study, we assessed the response to a
single morning dose of 10 mg of dapagliflozin in HNF1A-
MODY patients and compared to T2DM and GCK-MODY
subjects. SGLT2 inhibition was previously shown to be
clinically effective, safe and reduce cardiovascular out-
comes and mortality as well as death from any cause in
T2DM patients. Desirable effects of SGLT2 inhibitors
include no risk of hypoglycemia, body weight loss and a
small reduction of systolic blood pressure. The most com-
mon side effects are genitourinary infections [27–30]. The
SGLT2 inhibitor dapagliflozin also induces glycosuria in
healthy volunteers [19, 31]. While there was one case report
on a patient undergoing combined therapy with SU and
dapagliflozin in ABCC8-MODY [32], to the best of our
knowledge, no published studies have investigated the
effect of SGLT2 inhibitors in patients with GCK-MODY or
HNF1A-MODY. Here, in this short, 24 h clinical experi-
ment, we show for the first time that dapagliflozin induces
glycosuria in both HNF1A-MODY and GCK-MODY
patients and reduces FPG in GCK-MODY.
Our finding concerning dapagliflozin-induced glycosuria
in HNF1A mutation carriers is especially interesting. Gly-
cosuria in HNF1A-MODY results from reduced expression
of the SGLT2, which is under the transcriptional control of
HNF1A. In HNF1A-deficient animals, there is 80–90%
reduction in SGLT2 expression, which correlates with a
reduction in SGLT2 activity [10]. Furthermore, glycosuria
that occurs in HNF1A-deficient animals cannot be com-
pensated by the activity of other glucose transporters such
as SGLT1 (sodium/glucose co-transporter 1) and SGLT3
(sodium/glucose co-transporter 3) [10]. SGLT2 is respon-
sible for 90% of glucose reabsorption. However, in humans,
SGLT2 inhibitors block only 30–50% of the glucose load,
and a number of explanations have been proposed to
explain this phenomenon [33, 34]. One potential cause of
this effect is that SGLT1 works at submaximal capacity
under physiological conditions, with the residual capacity of
SGLT1 revealed upon SGLT2 inhibition [35]. However, the
precise mechanisms of incomplete inhibition of glucose
load with SGLT2 inhibitors and the interplay between
SGLT1 and SGLT2 transporters are not fully understood. In
our study, we observed no difference between HNF1A and
GCK mutation carriers in the effects of dapagliflozin
administration. This may mean that the degree of SGLT2
inhibition with dapagliflozin does not depend on baseline
activity of the SGLT2 protein, which is lower in HNF1A-
MODY patients. Surprisingly, the GCR change was greater
in both the HNF1A-MODY and GCK-MODY group than
in the T2DM group in our study. However, one must take
into consideration the significant clinical differences
observed among T2DM patients and those with MODY in
our study. Indeed, when we subsequently performed a
multivariate linear regression analysis, BMI was the only
significant predictive variable for GCR. Due to obvious
differences in the way the study groups were defined, we
were unable to match our T2DM and MODY patients
according to age and BMI.
Serum 1,5-AG level is a short-term marker of glycemic
control that competes with glucose for reabsorption [36]. It
was shown that 1,5-AG level is reduced in HNF1A-MODY;
however, its discriminative accuracy is not high enough for
it to be widely used in clinical practice [24, 37]. In our study
mean serum 1,5-AG level change after dapagliflozin
administration was statistically significant only in T2DM;
this finding is in contrast with change in glycosuria, which
was lowest in that group. Multivariate linear regression
Fig. 1 Receiver operating
characteristics (ROC) curves
showing the discriminative
accuracy of glucose to creatine
ratio (GCR) change after
dapagliflozin administration to
distinguish between the diabetes
subgroups: a.T2DM and
HNF1A-MODY; b T2DM and
GCK-MODY; and c HNF1A-
MODY and GCK-MODY
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showed that 1,5-AG level change depends on initial 1,5-AG
level—which was higher in T2DM than in both MODY
forms. A lower change in MODY could also results from
more stable glycemia over a period of a day. Moreover,
while 1,5-AG level is an independent marker of glycemic
control and glycosuria over 7–10 days, in our 24-h study the
full impact of dapagliflozin on the level of this marker could
not be seen due to the short-time nature of the experiment.
A proper diagnosis of MODY is crucial in order to
conduct adequate treatment. While genetic testing becomes
more and more available, there is still a need for cheap, easy
biochemical markers. Some of them were reported in earlier
research (apo-M, hs-CRP, 1,5-anhydroglucitol, ghrelin) [24,
38–40], nevertheless, none of them have been introduced to
the clinical practice. Drug response-based diagnostic tests
are quite common in medicine, especially in endocrinology,
for example, dexamethasone suppression tests, the clonidine
test, or the metoclopramide test. While our drug-based test
results are promising, one should be cautious with expec-
tations of using the test in routine practice.
Furthermore, we did not evaluate the long-term clinical
efficacy of dapagliflozin in MODY patients in the present
study. However, we did prove that dapagliflozin works in
MODY patients as well as in those with T2DM. Therefore,
SGLT2 inhibitors should be considered as an additional
therapeutic option in MODY patients in future. A safety
aspect that will have to be examined is a possible rise in
ketogenesis in these individuals, a phenomenon that was
earlier reported in T2DM and T1DM [41]. This seems to be
particularly important in HNFA1-MODY, as a few cases of
diabetic ketoacidosis were reported in this monogenic dia-
betes [42, 43].
Interestingly, we observed a significant drop in FPG in
GCK-MODY patients after one tablet of dapagliflozin. It is
a well known phenomenon that all pharmacological treat-
ment used so far in this form MODY was ineffective due to
counterregulatory mechanisms [11, 14, 15]. Most GCK-
MODY patients do not need any hypoglycemic treatment.
However, clinicians would probably consider treatment
initiation in some GCK-MODY individuals, especially in
patients with relatively common nonproliferative retino-
pathy, those with HbA1c >7.0% (53.0 mmol/mol) and/or
“overlapping” type 2 diabetes. Thus, identification of an
effective and safe drug for these subjects would be of
clinical value. It can be hypothesized that SGLT-2 inhibi-
tors could effectively lower blood glucose level in these
patients due to their specific mode of action.
Conclusion
To summarize, we have shown that a single dose of dapa-
gliflozin, an SGLT-2 inhibitor, induces higher glycosuria in
HNF1A- and GCK-MODY than in T2DM. There was no
difference in response to dapagliflozin between HNF1A and
GCK mutation carriers, despite a previously reported
reduction in SGLT2 expression among HNF1A-MODY
individuals. Whether flozins, such as dapagliflozin, are a
valid therapeutic option as an adjunctive therapy in these
MODY patients requires long-term clinical studies.
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